[{"data":1,"prerenderedAt":170},["ShallowReactive",2],{"drug-tigecycline":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":67,"warnings":77,"renal":87,"monitoring":88,"interactions":89,"review":90,"examples":93,"atc":98,"iran":100,"usApproval":112,"links":118,"populations":135},"tigecycline",1,{"fa":7,"en":8},"تیژسیکلین","Tigecycline","anti-infectives",{"fa":11,"en":12},"گلیسیل‌سیکلین","Glycylcycline",[14],{"name":15,"market":16},"Tygacil","US",[18,19,20],"tygacil","تایگاسیل","تیگسیکلین",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"vial-50","powder-for-injection","iv","50 mg vial",{"amount":28,"unit":29,"perUnit":30},50,"mg","vial",[16],[33],{"source":34,"section":35},"fda-tygacil","3",[37],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":29,"dose":48,"refs":50,"durationDays":53,"notes":56},"adult","intra-abdominal-infection",{"fa":41,"en":42},"عفونت عارضه‌دار پوست یا داخل شکم، پنومونی اکتسابی — ۱۰۰ mg سپس ۵۰ mg هر ۱۲ ساعت","cSSSI, cIAI, CAP — 100 mg, then 50 mg every 12 h",{"minAge":44},{"value":45,"unit":46},18,"year","fixed",{"perDose":28,"dosesPerDay":49},2,[51],{"source":34,"section":52},"2.1",{"min":54,"max":55},5,14,[57],{"text":58,"refs":61},{"fa":59,"en":60},"دوز اول ۱۰۰ mg. انفوزیون ۳۰ تا ۶۰ دقیقه. نارسایی شدید کبد: ۱۰۰ سپس ۲۵ mg هر ۱۲ ساعت. فیبرینوژن و انعقاد پایش شود.","First dose 100 mg. Infuse over 30–60 min. Severe hepatic impairment: 100 then 25 mg every 12 h. Monitor fibrinogen and coagulation.",[62,63,65],{"source":34,"section":52},{"source":34,"section":64},"2.2",{"source":34,"section":66},"2",[68],{"id":69,"severity":70,"text":71,"refs":74},"hyper","block",{"fa":72,"en":73},"حساسیت به تیژسیکلین.","Hypersensitivity to tigecycline.",[75],{"source":34,"section":76},"4",[78],{"text":79,"refs":82},{"fa":80,"en":81},"هشدار جعبه‌ای: افزایش مرگ از هر علت — فقط وقتی جایگزین مناسب نیست. کودکان: فقط اگر جایگزینی نیست.","Boxed warning: increased all-cause mortality — reserve for when alternatives are unsuitable. Children: only if no alternative.",[83,85],{"source":34,"section":84},"Boxed Warning",{"source":34,"section":86},"2.3",[],[],[],{"status":91,"reviewer":92,"date":92},"unverified",null,[94],{"regimen":38,"formulation":23,"input":95,"expect":97},{"ageYears":28,"weightKg":96},70,{"perDose":28,"dosesPerDay":49},[99],"J01AA12",{"status":101,"forms":102,"refs":107},"registered",[103],{"code":104,"en":105,"fa":106},"23169","TIGECYCLINE 50MG POWDER FOR INJ","فرآورده تزریقی تیجسایکلین ۵۰ میلی‌گرم",[108],{"source":109,"section":110,"url":111},"darooyab-generic","G-5339\u002FTigecycline","https:\u002F\u002Fwww.darooyab.ir\u002FG-5339\u002FTigecycline",{"kind":113,"refs":114,"id":117},"NDA",[115],{"source":34,"section":116},"SPL approval \u002F marketing category","NDA021821",[119,122,126,130,133],{"kind":120,"url":121,"label":117},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021821",{"kind":123,"url":124,"label":125},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=2ccdb48e-c14a-4eeb-348c-4920ccfd7465","FDA Tygacil",{"kind":127,"url":128,"label":129},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614002.html","Tigecycline Injection",{"kind":131,"url":132,"label":99},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J01AA12",{"kind":134,"url":111,"label":8},"darooyab",{"pregnancy":136,"lactation":145,"pediatric":153,"geriatric":162},{"level":137,"text":138,"quote":141,"refs":142},"caution",{"fa":139,"en":140},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary TYGACIL, like other tetracycline class antibacterial drugs, may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy [see Warnings and Precautions (5.7 , 5.8) , Data , and Use in Specific Populations …",[143],{"source":34,"section":144},"8.1",{"level":137,"text":146,"quote":149,"refs":150},{"fa":147,"en":148},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of tigecycline in human milk; however, tetracycline-class antibacterial drugs are present in breast milk.",[151],{"source":34,"section":152},"8.2",{"level":154,"text":155,"quote":158,"refs":159},"not-established",{"fa":156,"en":157},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients below the age of 18 years have not been established.",[160],{"source":34,"section":161},"8.4",{"level":137,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of subjects who received TYGACIL in Phase 3 clinical studies (n=2514), 664 were 65 and over, while 288 were 75 and over.",[168],{"source":34,"section":169},"8.5",1792191569364]